Cumulative incidence of systemic lupus erythematosus after incident primary immune thrombocytopenia and autoimmune haemolytic anaemia in France
| Patients | Primary ITP | Primary AIHA | ||||
| SLE/n | 1-year risk, % (95% CI) | 5-year risk, % (95% CI) | SLE/n | 1-year risk, % (95% CI) | 5-year risk, % (95% CI) | |
| All | 172/9589 | 1.0 (0.8 to 1.2) | 1.9 (1.6 to 2.2) | 38/4609 | 0.5 (0.3 to 0.7) | 1.0 (0.7 to 1.4) |
| Women | 150/5285 | 1.6 (1.3 to 2.0) | 2.9 (2.5 to 3.5) | 28/2653 | 0.6 (0.3 to 0.9) | 1.2 (0.8 to 1.7) |
| Men | 22/4304 | 0.3 (0.2 to 0.5) | 0.6 (0.4 to 0.9) | 10/1956 | 0.4 (0.2 to 0.7) | 0.7 (0.3 to 1.3) |
| 18–45 years | 102/2844 | 2.0 (1.6 to 2.6) | 3.8 (3.1 to 4.6) | 23/699 | 1.9 (1.0 to 3.1) | 4.2 (2.7 to 6.3) |
| Women | 96/1910 | 2.8 (2.1 to 3.6) | 5.3 (4.3 to 6.5) | 15/418 | 1.7 (0.7 to 3.3) | 4.5 (2.5 to 7.2) |
| Men | 6/934 | 0.5 (0.2 to 1.2) | 0.7 (0.3 to 1.5) | 8/281 | 2.1 (0.9 to 4.4) | 3.9 (1.6 to 7.6) |
| 45–65 years | 40/2374 | 0.9 (0.6 to 1.4) | 1.8 (1.3 to 2.4) | 9/1017 | 0.5 (0.2 to 1.1) | 0.9 (0.4 to 1.7) |
| Women | 31/1289 | 1.3 (0.8 to 2.1) | 2.4 (1.7 to 3.4) | 8/589 | 0.8 (0.3 to 1.9) | 1.2 (0.6 to 2.4) |
| Men | 9/1085 | 0.5 (0.2 to 1.0) | 1.0 (0.5 to 1.9) | 1/428 | 0 | 0.4 (0.0 to 2.3) |
| ≥65 years | 30/4371 | 0.4 (0.3 to 0.6) | 0.7 (0.5 to 1.0) | 6/2893 | 0.1 (0.0 to 0.3) | 0.2 (0.1 to 0.5) |
| Women | 23/2086 | 0.7 (0.4 to 1.1) | 1.1 (0.7 to 1.7) | 5/1646 | 0.2 (0.1 to 0.5) | 0.3 (0.1 to 0.7) |
| Men | 7/2285 | 0.2 (0.1 to 0.4) | 0.3 (0.2 to 0.7) | 1/1247 | 0.1 (0.0 to 0.4) | 0.1 (0.0 to 0.4) |
AIHA, autoimmune haemolytic anaemia; ITP, immune thrombocytopenia; SLE, Systemic lupus erythematosus.